2) I am Dr. Aakash Desai (@ADesaiMD) from @MayoHemOnc @MayoCancerCare @HemOncFellows @Oncoalert and now we are covering @myESMO #ESMOImmuno22 updates/review on “Biomarker Targeted therapies” in #LCSM! pic.twitter.com/43wAJCH3gR
— pulmmed_ce (@Pulmmed_CE) January 5, 2023
4) #LCSM treatment has come a long way from chemotherapy only approaches to integration of #TKIs and now #ADCs!
— pulmmed_ce (@Pulmmed_CE) January 5, 2023
➡️ Many next #gen TKI molecules and ADCs in development #LCSM! https://t.co/Ifu5Ar4c2C pic.twitter.com/EcLwXOK4P7
6) At @myESMO #ESMOImmuno22 we saw data on #adagrasib (#KRASG12C inhibitor) with #immunotherapy, with some studies on newer #IO combinations! In this 🧵 we will discuss #biomarker based #LCSM approaches with some updates! @HemOncFellows @Oncbrothers pic.twitter.com/NhN0yTyPgd
— pulmmed_ce (@Pulmmed_CE) January 5, 2023
8) #EGFR really the first targeted for #LCSM
— pulmmed_ce (@Pulmmed_CE) January 5, 2023
✅Not all EGFR mutations are the same!
✅Osimertinib=tx for most activating #EGFR mutations
based on #ADAURA trial adjuvantly now ➡️Osimertinib 80 mg once daily for 3 years https://t.co/ks1YsyjNKO pic.twitter.com/8do2ThYHtd
10) #KRASG12 now druggable in 2L! Really exciting year for #KRASG12C #LCSM with 📊📈presented @AACR @ASCO#ASCO22 @IASLC#WCLC22 and now @myESMO #ESMO22 #ESMOImmuno22! Here’s #Onc1Slider on #KRASG12C #LCSM
— pulmmed_ce (@Pulmmed_CE) January 5, 2023
To 🔄🧠! pic.twitter.com/BscLKbTzai
12) Now @myESMO #ESMOImmuno22 Dr. Janne presented (KRYSTAL1/7) data on #adagrasib + #pembrolizumab 1L
— pulmmed_ce (@Pulmmed_CE) January 5, 2023
🛑G3>= TRAEs: 44%, 0 grade 5‼️
➡️ORR: 49% @KRASKickers #LCSM pic.twitter.com/XX5481s2aj
14) Newer emerging #biomarkers with current 2L approvals are:
— pulmmed_ce (@Pulmmed_CE) January 5, 2023
➡️ EGFR ex20 ins: Capmatinib, Tepotinib: https://t.co/Mik8jrk7k5
➡️ ERBB2 mutations: TDx-d https://t.co/Qn3Z4av7gP pic.twitter.com/0K9vjCRslI
16) It’s C!
— pulmmed_ce (@Pulmmed_CE) January 5, 2023
Biomarkers for the #antibody-drug conjugates #ADCs are under investigation but keen interest in:
➡️ HER2, HER3, TROP2, MET, CEACAM5 for #LCSM #NSCLC
➡️ DLL3 for #SCLChttps://t.co/zqVqiKzZtM @Alfdoc2 pic.twitter.com/BSxLMZYrNr
18) As we look forward, more 🎯💊 therapies we need novel targets, #CEACAM5 #overexpressed in #LCSM
— pulmmed_ce (@Pulmmed_CE) January 5, 2023
➡️ 38% AdenoCA, 20% SqCC stain for #CEACAM5 @Oncoalert https://t.co/6h3QzIQjJW pic.twitter.com/BVzezNgXNb
20) Sneak peek into #ADCs also entering the #metastatic #oncogene driven #LCSM #NSCLC presented at #ASCO22 @ASCO
— pulmmed_ce (@Pulmmed_CE) January 5, 2023
➡️ Telisotuzumab Vedotin (MET ADC) with #osimertinib
➡️ Dato-Dxd
➡️ Patritumab Dxd #EGFRm #LCSM @EGFRResisters pic.twitter.com/0rBr2v4maa
22) Now go to https://t.co/ckVKmIyO7g to claim your 🆓CE/#CME 🇺🇸🇨🇦🇪🇺🇬🇧. FOLLOW US here @pulmmed_ce for more #accredited #tweetorials by expert authors! pic.twitter.com/axUtQVjBah
— pulmmed_ce (@Pulmmed_CE) January 5, 2023